Clinical Trial Update: Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and pharmacokinetics of raltegravir in HIV-1-exposed newborn infants at risk of acquiring HIV-1 infection; completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• HIV Infection in Newborns

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2020-07-17